Pharmaceutical companies have been reluctant to take part in cross-country health technology assessments (HTAs) offered by groups such as the recently revamped Joint Nordic HTA-Bodies (JNHB). Nevertheless, these initiatives are here to stay and companies should embrace the opportunities they offer, experts at the JNHB told the Pink Sheet in an interview.
Nordic HTA Collaboration: Feel The Fear And Do It Anyway
It is time for companies to take part in cross-country health technology assessments and stop asking “what’s in it for me?”
More from Health Technology Assessment
More from Pink Sheet
• By
Pharmaceutical companies are being encouraged to reach out to NICE in relation to its HTA Innovation Lab, which provides a sandbox environment in which the health technology assessment body can test new methods of evaluating “innovative and disruptive” therapies.
• By
The Brazilian medicines regulator will also offer more clarity on the requirements for radiopharmaceuticals that are exempt from registration.
• By
South Korea announces planned revisions to a government scheme to designate "innovative" biopharma companies amid allegations of "discrimination" against foreign firms.